Phio Secures U.S. cGMP Manufacturing for Lead Drug PH-762, Paving Way for Advanced Trials
Summary
Phio Pharmaceuticals has announced a cGMP manufacturing agreement with a U.S. source for its lead drug candidate, PH-762. This critical operational milestone follows the encouraging Phase 1b clinical study results for PH-762 in cutaneous carcinomas, which the company reported last week. Securing a cGMP manufacturing partner is a significant de-risking event, ensuring the supply of clinical-grade material for future trials and laying the groundwork for potential commercial production. This agreement is essential for advancing PH-762 through later-stage clinical development and towards potential regulatory approval. Investors should watch for further updates on FDA engagement regarding next-stage clinical development, targeted for Q2 2026.
At the time of this announcement, PHIO was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6M. The 52-week trading range was $0.81 to $4.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.